ESOPMay 29, 2026, 05:07 PM
Tenaya Therapeutics Stockholders Approve Equity Plan with 6.5M Share Increase
AI Summary
Tenaya Therapeutics, Inc. stockholders approved the Amended and Restated 2021 Equity Incentive Plan at the Annual Meeting on May 27, 2026. This plan includes a one-time increase of 6,509,966 shares (approximately 3% of outstanding shares) reserved for issuance and modifies the annual evergreen provision. Additionally, stockholders elected three Class II Directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan.
- The plan increases shares reserved for issuance by 6,509,966, approximately 3% of outstanding shares.
- The annual evergreen provision was amended to remove the 4 million share limit, while maintaining the 4% of outstanding shares increase.
- Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen were elected as Class II Directors.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Price Impact
More from TNYA